Health Care | Pharmaceuticals, Biotechnology & Life Sciences | Biotechnology
NASDAQ | Common Stock
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders.
The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases.
It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases.
The company has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat.
Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.
As of March 1, 2023, Albireo Pharma, Inc. operates as a subsidiary of Ipsen Biopharmaceuticals, Inc..
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 8, 22 | -1.92 Decreased by -166.21% | -1.06 Decreased by -81.13% |
| Aug 15, 22 | -2.04 Decreased by -7.37% | -1.65 Decreased by -23.64% |
| May 16, 22 | -2.19 Increased by +4.37% | -1.85 Decreased by -18.38% |
| Mar 1, 22 | -0.57 Increased by +56.15% | -1.35 Increased by +57.78% |
| Nov 4, 21 | 2.90 Increased by +247.96% | -0.38 Increased by +863.16% |
| Aug 5, 21 | -1.90 Decreased by -37.68% | -1.97 Increased by +3.55% |
| May 6, 21 | -2.29 Decreased by -2.69% | -1.77 Decreased by -29.38% |
| Feb 25, 21 | -1.30 Decreased by -128.07% | -1.94 Increased by +32.99% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 22 | 9.83 M Increased by +168.34% | -37.80 M Decreased by -166.22% | Decreased by -384.46% Decreased by -124.68% |
| Jun 30, 22 | 8.21 M Increased by +237.97% | -39.95 M Decreased by -9.69% | Decreased by -486.83% Increased by +67.55% |
| Mar 31, 22 | 6.83 M Increased by +247.51% | -42.43 M Increased by +2.97% | Decreased by -621.11% Increased by +72.08% |
| Dec 31, 21 | 32.52 M Increased by +1.10 K% | -10.96 M Increased by +55.80% | Decreased by -33.71% Increased by +96.31% |
| Sep 30, 21 | 3.66 M Increased by +71.94% | 57.09 M Increased by +285.69% | Increased by +1.56 K% Increased by +208.00% |
| Jun 30, 21 | 2.43 M Increased by +26.99% | -36.42 M Decreased by -76.78% | Decreased by -1.50 K% Decreased by -39.21% |
| Mar 31, 21 | 1.97 M Increased by +26.92% | -43.73 M Decreased by -38.89% | Decreased by -2.22 K% Decreased by -9.43% |
| Dec 31, 20 | 2.72 M Decreased by -57.77% | -24.80 M Decreased by -229.69% | Decreased by -913.07% Decreased by -680.64% |